FDA Draft Guidelines for AI and the Need for Ethical Frameworks

This Viewpoint discusses the US Food and Drug Administration (FDA) guidance on the role of artificial intelligence (AI) in the drug and biological product life cycle, including the consideration of questions of uncertainty, accuracy, reliability, fit for purpose, and the facilitation of responsible use of AI in drug and biological product development.